Log In
BCIQ
Print this Print this
 

vanoxerine (GBR-12909)

  Manage Alerts
Collapse Summary General Information
Company Laguna Pharmaceuticals Inc.
DescriptionOral inhibitor of L-type calcium and sodium channels and potassium channel Kv11.1 (KCNH2; hERG)
Molecular Target Potassium channel Kv11.1 (KCNH2) (hERG) ; Sodium channel
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationFibrillation
Indication DetailsTreat symptomatic atrial fibrillation (AF) or flutter of recent onset
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today